| Document |
Document Title |
|
WO/2024/015861A1 |
Provided herein are methods of preparation of compound 101. Also provided are intermediate compounds useful in the preparation of compound 101, and methods of preparation of those intermediate compounds.
|
|
WO/2023/193341A1 |
Provided are a sphingolipid compound shown in formula (I), a liposome containing the sphingolipid compound, and an application. The sphingolipid compound is prepared by taking a long-chain alkyl group as a hydrophobic tail part, and bond...
|
|
WO/2023/167269A1 |
A compound represented by formula (1). (In formula (1), A and B satisfy the relation of (I) or (II). (I): One of A and B is a group represented by formula (2). (II): A and B both independently represent a group represented by formula (2)...
|
|
WO/2023/164544A2 |
Provided herein, inter alia, novel ionizable cationic lipids, lipid nanoparticles comprising the novel ionizable cationic lipids and methods of using said nanoparticles.
|
|
WO/2023/118637A1 |
The present invention relates to metal-organic structures. More specifically, it relates to metal-ligand structures having a mesocate architecture. The present invention also relates to the method for producing said structures and the us...
|
|
WO/2023/091679A1 |
Provided herein are compounds and methods for modulating claudin-1 (CLDN1). More particularly, provided are inhibitors claudin-1 and the uses of such inhibitors in regulating diseases and disorders, e.g., to treat cancer.
|
|
WO/2023/085894A1 |
The present invention relates to a novel thiourea derivative as an activator of RORα and a pharmaceutical composition comprising same. A compound according to the present invention is expected to be effective in the treatment and preven...
|
|
WO/2023/054120A1 |
Provided is a method for separating and recovering metal ions wherein an oil phase containing an extraction agent is mixed with an aqueous phase that contains at least two metal ion species including a group 3 to group 16 metal ion and t...
|
|
WO/2023/044343A1 |
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
|
|
WO/2023/036945A1 |
The invention relates to a compound of formula (I) wherein A is NH or CH2; G1 is a linear or a cyclic alkyl; Y1 is CH or N; Y2 is O, N or CH, W is O, N or CH; Z is NH or O; X1 and X2 and R, and R1 to R8 are functional groups.
|
|
WO/2023/017518A1 |
The invention relates to a novel and efficient saflufenacil synthesis and the preparation of novel key intermediates in the process of Saflufenacil synthesis. The process includes preparing compounds of the Formula I wherein R1i is a hyd...
|
|
WO/2023/017400A1 |
Novel compounds of general Formula (I) derived from the conjugation of the native metformin drug to molecular moieties endowed with the property of releasing hydrogen sulfide are described. The compounds forming the object of the present...
|
|
WO/2022/245627A1 |
In one aspect, the application relates to sulfonyl chalcogenide urea derivatives of Formula II, including sulfonyl thioureas and sulfonyl selenoureas, and methods of making the same, wherein the methods can be carried out under mild cond...
|
|
WO/2022/236270A1 |
A method for treating a subject in need thereof having a bone or blood cancer, or a cancer that metastasizes to bone that includes administering to the subject an effective amount of hydroxyureamethyl acylfulvene.
|
|
WO/2022/229734A1 |
The invention relates to an initiator system for curing a dental composition, the initiator system comprising a hydroperoxide component, a transition metal component, a polymerizable thiourea component, the polymerizable thiourea compone...
|
|
WO/2022/153003A1 |
The present invention relates to the field of perfumes and flavourings. More particularly, it relates to valencene derivatives and the use thereof as a perfuming or flavouring agent. It also relates to a perfuming or flavouring compositi...
|
|
WO/2015/136292A9 |
The invention relates to a DDX3X inhibitorfor use in the treatment of pneumovirus infection in a mammal, wherein the DDX3X inhibitor may be a compound of Formula (I) wherein y, Z, R1, X, L, Ra and Rb are as defined herein. The invention ...
|
|
WO/2022/065802A1 |
A polythiol composition according to exemplified embodiments comprises a first polythiol compound, and a second polythiol compound having a larger molecular weight than the first polythiol compound and having a number of functional group...
|
|
WO/2022/029358A1 |
The present invention relates to a compound 1 or 2 or a composition comprising same. The invention also relates to a method for obtaining compound 1 or 2, and to the use of the compounds to detect GHB in beverages. The invention also inc...
|
|
WO/2021/255279A1 |
The invention relates to novel compounds of formulae (I') and (II') for the treatment, alleviation or prevention of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a compone...
|
|
WO/2021/175822A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and/or N-oxides of those compounds, can be used as pesticides.
|
|
WO/2021/165187A1 |
The invention relates to a process for preparing 2-(phenylimino)-3-alkyl-1,3-thiazolidin-4-ones of the general formula (I), wherein Y1, Y2, R1, R2 and R3 have the meanings indicated in the description.
|
|
WO/2021/162096A1 |
The present invention relates to a method for producing 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-metho
xy-N-methylquinoline-6-carboxamide, the method comprising a step for linking 4-(4-amino-2-fluorophenoxy)-7-methoxy-N-met...
|
|
WO/2021/162097A1 |
The present invention relates to: 4-hydroxy-7-methoxy-N-methylquinoline-6-carboxamide, 7-methoxy-N-methy-4-(4-(3-(2-phenylacetyl)thioureido)phenoxy
)quinoline-6-carboxamide, 4-(2-fluoro-4-(2-phenylacetamide)phenoxy)-7-methoxy-N-methyl
qu...
|
|
WO/2021/136431A1 |
Disclosed is a series of benzo[d][1,2,3]triazole ether compounds, and specifically disclosed are a compound shown in formula (I) and pharmaceutically acceptable salts thereof.
|
|
WO/2021/107478A1 |
The present invention relates to a method for preparing 1-(4-benzyloxy-benzyl)-3-methyl-thiourea and a method for preparing a novel stable crystalline form A of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea.
|
|
WO/2021/107476A1 |
The present invention relates to a 1-(4-benzyloxy-benzyl)-3-methyl-thiourea compound in crystalline forms A, B, C, or amorphous form, a method for preparing the compound in the crystalline or amorphous forms, and a use of the compound fo...
|
|
WO/2021/102266A1 |
Di alkenyl succinic amide acids and processes for making and using same. The di alkenyl succinic amide acid can have a chemical formula of (I): where R1 and R2 can independently be a linear or branched C8 to C24 alkenyl group, Z1, Z2, Z3...
|
|
WO/2021/073131A1 |
Provided in the present invention are a medicament for effectively killing drug-resistant disease bacteria and an application thereof in inhibiting drug-resistant disease bacteria. Specifically, provided in the present invention is a com...
|
|
WO/2020/109506A1 |
The invention relates to compounds of formula (I) as follows: (I) wherein X1 and X2, identical or different, are NR5or a sulfur atom, Y is a group (C1-C10)alkanediyl, Ar1 and Ar2, identical or different, are an aryl group optionally subs...
|
|
WO/2020/071961A1 |
The invention relates to an agent for the targeted therapy of solid malignant tumours which contains as active ingredient dichloroacetate 1-isobutanoyl-2-isopropyl isothiourea having the structural formula shown. Said agent exhibits a co...
|
|
WO/2020/061367A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2020/047668A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers ...
|
|
WO/2020/010143A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to tre...
|
|
WO/2019/243414A1 |
The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.
|
|
WO/2019/189762A1 |
Provided is a method for manufacturing a polythiol compound, including reacting thiourea having an ammonium thiocyanate content of 0.05% by mass and a polyol compound, and obtaining an isothiuronium salt.
|
|
WO/2019/179436A1 |
The present invention relates to the field of pharmaceutical chemistry. Disclosed are an acid amide compound and use thereof in the treatment of cancers. Disclosed is use of an acid amide compound represented by formula (I), or its cryst...
|
|
WO/2019/160798A1 |
Accelerator solutions containing transition metal complexes based on organic ligands having one or more S-C-N, S-C-C-N, or S-C(=S)-S moieties are useful for accelerating the peroxide cure of resins such as unsaturated polyester resins.
|
|
WO/2019/078246A1 |
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as an IDO/TDO inhibitor. The compound represented by formula (I) or a pharmaceutically acceptable salt thereof can, for exam...
|
|
WO/2018/227300A1 |
Novel urea, thiourea and squaramide compounds and bioisosteres thereof of formulas (I) and (VI) and the use thereof for treating, attenuating, inhibiting or preventing inflammation and inflammation-related pathologies are described herein.
|
|
WO/2018/219309A1 |
The present invention relates to a vinylarene derivative which modulates or inhibits the enzymatic activity of indoleamine 2,3-dioxygenase 1 (IDO-1), and the use thereof, and further relates to a vinylarene derivative and the use thereof...
|
|
WO/2018/172783A1 |
There is described a method of reducing polymer tar build-up in the production of methyl methacrylate and/or methacrylic acid by the acetone cyanohydrin process. In the method a stabiliser is contacted with the amide stage reaction mediu...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/133756A1 |
The present invention relates to a targeted autophagy agonist and an application thereof in the treatment of neurodegenerative diseases, pertaining to the technical field of pharmaceuticals for the treatment of neurodegenerative diseases...
|
|
WO/2017/168419A9 |
Disclosed methyl styrene farmin compounds, and crosslinked polymeric backbones comprising same. Further disclosed microsized and nanosized polymeric particles comprising polyisothiouronium methylstyrene (PITMS) and/or poly(methyl styrene...
|
|
WO/2018/042460A1 |
The present invention discloses sulphur functionalized polyurea composite of Formula (I) and Formula (II) that provides an insoluble solid support for effective removal of metal residues from solvent streams and other reservoirs and to t...
|
|
WO/2018/028665A1 |
Provided is a method for preparing an intermediate of 6-arylaminopyridonecarboxamide compound as an MEK inhibitor, comprising preparing a compound of formula (III) as an intermediate of 6-arylaminopyridonecarboxamide compound using a com...
|
|
WO/2017/170826A1 |
The purpose of the invention is to provide a compound useful in the prevention or treatment of diabetes, obesity, and conditions related thereto. The present invention relates to an enhancing agent for glucagon-like peptide-1 receptor ac...
|
|
WO/2017/099237A1 |
A compound represented by formula (I) and having a property of modulating the activity of an androgen receptor, or a pharmaceutically acceptable salt of the compound. X represents S or O; Z represents (Ra)n-A-(CR13R14)0-1-(CR11R12)0-1-; ...
|
|
WO/2017/096430A1 |
The present invention relates to hydroxamic acid-based compounds, their intermediates, preparation and uses. The compounds are useful in imaging, particularly for the imaging of tumours and cancer, and especially for the imaging of prost...
|
